Novamind, a Toronto-based mental health company that specializes in psychedelic-assisted therapy, announced that common shares of the company were to begin trading on the Canadian Securities Exchange on Tuesday.
Novamind has developed a network of mental health clinics and clinical research sites over the past 18 months. The company provides ketamine-assisted psychotherapy and other treatments through its Cedar Psychiatry clinics. The company also runs Cedar Clinical Research, a contract research organization that specializes in clinical trials and research for psychedelic medicine.
The public listing, in combination with the recent closing of an oversubscribed $10 million Canadian private placement, has positioned Novamind to expand its base of operations and also pursue acquisitions, CEO and director Yaron Conforti said in a statement.